Xenetic Biosciences, Inc. Reports Third Quarter 2024 Financial Results
Establishing growing body of preclinical data evaluating the DNase-based oncology platform across a number of high-value oncology indications
22nd Century Group Reports Third Quarter 2024 Financial Results
Remains on Path to Cash Positive Operations in Q1 2025Commencing Growth Strategy Leveraging Both Internal and External Brand Assets Across
HealthWarehouse.com Reports Results for Third Quarter 2024
HealthWarehouse.com provides a platform focused on increasing access to and reducing costs of healthcare products for consumers and business partners nationwide. Joseph Peters, President and CEO, commented,
Exodus Reports Third Quarter 2024 Results
Exodus Movement, Inc. (OTCQX: EXOD), (the “Company” or “Exodus”) the leading self-custodial cryptocurrency software platform, today announced its results for the third
Processa Pharmaceuticals Reports Third Quarter Business Highlights and Financial Results
First patient dosed in Phase 2 clinical trial with NGC-Cap for metastatic breast cancer Positive data from preclinical studies support NGC-Iri’s
Liquidia Corporation Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today reported financial results for the third quarter ended September 30,
Processa Pharmaceuticals Reports Q3 2024 Financial Results
Processa Pharmaceuticals, Inc. ( (PCSA) ) has released its Q3 earnings. Here is a breakdown of the information Processa Pharmaceuticals, Inc.
Yahoo Finance1mon
Processa Pharmaceuticals doses first subject in Phase II breast cancer trial
Processa Pharmaceuticals has dosed the first subject in its Phase II clinical trial of Next Generation Capecitabine (NGC-Cap) to treat patients with advanced or metastatic breast cancer.
Morningstar26d
Processa Pharmaceuticals Inc PCSA
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
The Globe and Mail1mon
Processa Pharmaceuticals Announces First Patient Dosed in Phase 2 Clinical Trial of NGC-Cap in Metastatic Breast Cancer
Oct. 02, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (Processa or the Company), a clinical-stage pharmaceutical company focused on developing the next generation of ...
Wall Street Journal29d
Processa Pharmaceuticals Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...